Americans with food and sting allergies can now find an alternative to epinephrine auto-injectors in pharmacies across the United States.
Sandoz Inc. announced on July 9 the nationwide retail launch of Symjepi, the pre-filled epinephrine syringe, in both adult (0.3 mg) and pediatric (0.15 mg) doses. Sandoz is the marketing and commercial partner of Adamis Pharmaceuticals, which developed the epinephrine product.
The pre-insurance retail price for a two-pack of the Symjepi is $250. The company also has a savings program, which allows eligible patients pay as little as $0 for a syringe set.
For patients who are looking to purchase Symjepi, Allison Schneider, director of communications at Sandoz, recommends that an allergist writes a prescription directly for Symjepi or writes the prescription as “epinephrine injection” rather than “epinephrine auto-injector.”
“[This is] so that pharmacies can ensure patients receive epinephrine medicine alternatives during their first attempt to fill their prescription,” Schneider told Allergic Living.
The retail rollout of Symjepi comes at a crucial time for patients with food allergies who have faced ongoing shortages of Mylan’s NV’s brand-name EpiPen and its generic equivalent. (Kaléo’s Auvi-Q compact auto-injectors and Teva’s generic auto-injectors are not in shortage.)
“Patients and health-care professionals are trying to navigate this critical shortage of self-injectable epinephrine products, which is why Sandoz is immediately making Symjepi available in adult and pediatric doses to patients at their local pharmacies,” Carol Lynch, president of Sandoz, said in a press release.
Dr. Dennis Carlo, president and CEO of Adamis, added: “we expect that Symjepi will play a role in ending the chronic shortages of epinephrine injection products in the U.S.”
The syringe is about four inches long and the design is more basic than an auto-injector, which has a mechanism to fire the needle along with the medicine. With a pre-filled syringe, one presses down on a plunger to give the medicine via a needle. The 0.3 mg-dose is intended for patients who weigh 66 pounds or more. The lower-dose device is meant for younger children, who weigh between 33 and 66 pounds.